Early recurrence and the need for re-resection following Photodynamic diagnosis–assisted Transurethral Resection of Bladder Tumours: Multi-centre real-world experience of the UK PDD Users Group. (January 2021)
- Record Type:
- Journal Article
- Title:
- Early recurrence and the need for re-resection following Photodynamic diagnosis–assisted Transurethral Resection of Bladder Tumours: Multi-centre real-world experience of the UK PDD Users Group. (January 2021)
- Main Title:
- Early recurrence and the need for re-resection following Photodynamic diagnosis–assisted Transurethral Resection of Bladder Tumours: Multi-centre real-world experience of the UK PDD Users Group
- Authors:
- Mariappan, Paramananthan
Bunce, Colin
Cresswell, Jo
Shamsuddin, Altaf
Crundwell, Malcolm
Donat, Roland
Hurle, Rhidian A
Zachou, Alexandra
Stewart, Sarah
Hartley, Louise J
Mostafid, Hugh - Abstract:
- Objective: This study aimed to investigate the association between Photodynamic Diagnosis (PDD) with hexaminolevulinate (HAL) and the rate of complete resection and disease persistence at first follow-up cystoscopy for non-muscle-invasive bladder cancer (NMIBC) in UK real-world practice. Methods: Audit data were pooled from six UK centres where HAL PDD was used in patients with a new NMIBC diagnosis undergoing transurethral resection of bladder tumours (TURBT) since 2008. Patients received adjunctive intra-vesical therapy and surveillance in line with European and UK guidelines, including early re-resection in high-grade NMIBC. Results: PDD-assisted TURBT was done in 837 patients with new NMIBC. The detrusor muscle was present in 69.4% of cases. At early re-TURBT in 207 high-risk patients, 13.0% had residual disease. Multifocal disease was the most significant factor in increasing the rate of residual disease (odds ratio excluding cases of CIS=4.1; 95% confidence interval 1.5–11.3). The recurrence rate at first follow-up cystoscopy (RRFFC) was 10.6% (8.9% in patients with complete initial TURBT). In the historical cohort undergoing good-quality white-light TURBT, RRFFC was 31%; 40.5% of high-risk patients had residual disease at early re-TURBT. Conclusion: HAL PDD may increase the rates of complete resection, reducing the risk of early recurrence and the need for routine re-resection in high-grade NMIBC. Level of evidence: 2b.
- Is Part Of:
- Journal of clinical urology. Volume 14:Number 1(2021)
- Journal:
- Journal of clinical urology
- Issue:
- Volume 14:Number 1(2021)
- Issue Display:
- Volume 14, Issue 1 (2021)
- Year:
- 2021
- Volume:
- 14
- Issue:
- 1
- Issue Sort Value:
- 2021-0014-0001-0000
- Page Start:
- 65
- Page End:
- 72
- Publication Date:
- 2021-01
- Subjects:
- Fluorescence cystoscopy -- hexaminolevulinate -- recurrence -- transitional cell carcinoma -- urinary bladder neoplasms -- urothelial carcinoma
Genitourinary organs -- Surgery -- Periodicals
Genitourinary organs -- Diseases -- Periodicals
Urology -- Periodicals
616.6005 - Journal URLs:
- http://uro.sagepub.com/ ↗
http://www.uk.sagepub.com/home.nav ↗
http://www.uk.sagepub.com/journals/Journal202162 ↗ - DOI:
- 10.1177/2051415819890464 ↗
- Languages:
- English
- ISSNs:
- 2051-4158
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 14912.xml